Sun Pharma Reports 10% Revenue Growth as Organon Acquisition Nears Completion
India's largest drugmaker posted double-digit sales growth in Q1 FY2027, driven by innovative medicines and branded generics, despite U.S. generic headwinds.
Revenue Growth Masks Regional Divergence
Sun Pharmaceutical Industries reported consolidated sales of INR 151,836 million for the first quarter of fiscal 2027, representing growth of 10.1% year-over-year (earnings call, 2026-07-31). However, the headline figure masked contrasting performance across geographies, with the U.S. business declining 9.7% to $427 million while India formulations surged 16% to INR 54,749 million.
The U.S. decline was "largely due to lenalidomide erosion, but also due to additional competition in certain products," according to CEO for North America Richard Ascroft (earnings call, 2026-07-31). The company also experienced seasonality in Levulan, its actinic keratosis treatment, which Ascroft noted would likely continue into the next quarter.
Innovative Medicines Drive Margin Expansion
Global innovative medicines sales climbed 12.8% to $351 million, accounting for 21.9% of total sales (earnings call, 2026-07-31). The segment's growth across products including ILUMYA, ODOMZO, and CEQUA helped drive gross margins to 80.5%, up from the prior-year period.
CFO Jayashree Satagopan attributed the margin expansion to "better product mix," specifically highlighting growth in both branded generics and innovative medicines (earnings call, 2026-07-31). However, EBITDA margins of 28.9% were "slightly lower" than Q1 FY2026, though Satagopan noted that "adjusted for that [lenalidomide benefit], EBITDA margins were higher year-on-year."
The company reported positive momentum for recent launches Leqselvi and Unloxcyt. Leqselvi "surpassed 1,000 prescribers" in June and "delivered our strongest month since launch," while Unloxcyt continued to see "month-over-month growth as more cancer centers and integrated health systems add Unloxcyt to their formularies" (earnings call, 2026-07-31).
India Business Strengthens Market Position
Sun Pharma maintained its #1 ranking in India with 8.5% market share, up from 8.2% in the prior period, according to Pharmarack data (earnings call, 2026-07-31). Managing Director Kirti Ganorkar highlighted that the company's 30.4% PharmaTrack growth was "driven primarily by strong volume expansion and new product launches," with volume growth of 5.4% comparing favorably to the 2% Indian pharmaceutical market average.
The company became the "#2 generic semaglutide injectable player" in India and is "the only company in India offering semaglutide auto-injector" (earnings call, 2026-07-31). Sun Pharma also received approvals for generic semaglutide in Brazil and South Africa, with the South African launch already completed.
Organon Acquisition On Track
Chairman Dilip Shanghvi confirmed that Organon shareholders have approved the acquisition, which "is on track to close by early 2027" (earnings call, 2026-07-31). The company expects completion in Q4 FY2027, with an integration management office already working on day-one preparedness.
The acquisition led to exceptional charges of INR 1,617 million in the quarter for transaction-related costs, with "additional charges on this account in the subsequent quarters" expected to be "somewhat back-ended with a substantial part being accrued at closing" (earnings call, 2026-07-31).
Consolidated R&D investment stood at INR 8,264 million, or 5.4% of sales, with innovative R&D accounting for 30% of total spend (earnings call, 2026-07-31). The company maintained a strong balance sheet with net cash of $3.4 billion at the consolidated level.
This article was generated by MarginX from the earnings call on 2026-07-31. It is not investment advice.